Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: The nucleoside inflammation, coagulation and endothelial function (NICE) study

Antiviral Therapy

Volumn 19, Issue 2, 2014, Pages 141-147

  Wohl, David A ^a   Arnoczy, Gretchen ^a   Fichtenbaum, Carl J ^b   Campbell, Thomas ^c   Taiwo, Babafemi ^d   Hicks, Charles ^e   McComsey, Grace A ^f   Koletar, Susan ^g   Sax, Paul ^h   Tebas, Pablo ⁱ   Ha, Belinda ^j   Massengale, Kelly ^a   Walsh, Kendall ^a   Stein, James H ^k  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j GLAXOSMITHKLINE   (United States)

^k UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; CD4 ANTIGEN; D DIMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LIPID; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER; PHOSPHONIC ACID DERIVATIVE;

ADULT; AGE; ARTERY DIAMETER; ARTICLE; BLOOD CLOTTING DISORDER; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ULTRASOUND; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; DRUG EFFECTS; HIV INFECTIONS; INFLAMMATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR; VASCULAR ENDOTHELIUM;

ADENINE; ADULT; ANTI-HIV AGENTS; BIOMARKERS; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; DIDEOXYNUCLEOSIDES; ENDOTHELIUM, VASCULAR; FEMALE; HIV INFECTIONS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RISK FACTORS; TENOFOVIR; ZIDOVUDINE;

EID: 84896695560     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2681     Document Type: Article

References (29)

1. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet 2008; 371:1417-1426.
2. Strategies for Management of Anti-Retroviral Therapy/INSIGHT Study Group, DAD Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-F24.
3. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a casecontrol study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170:1228-1238.
4. Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011; 53:84-91.
5. Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-Term results from ACTG A5001/ALLRT. Clin Infect Dis 2011; 52:929-940.
6. Ding X, Andraca-Carrera E, Cooper C, et al. No association of myocardial infarction with ABC use: an FDA meta-Analysis. 18th Conference on Retroviruses & Opportunistic Infections. 27 February-2 March 2011, Boston, MA, USA. Abstract 808.
7. Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease events: a meta-Analysis of published and unpublished data. AIDS 2011; 25:1993-2004.
8. Satchell CS, O'Halloran JA, Cotter AG, et al. Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy. J Infect Dis 2011; 204:1202-1210.
9. Hsue PY, Hunt PW, Wu Y, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009; 23:2021-2027.
10. McComsey GA, Kitch D, Daar ES, et al. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir: ACTG A5224 s, A5202 substudy. AIDS 2012; 26:1371-1385.
11. Shikuma CM, Ribaudo HJ, Zheng Y, et al. Change in highsensitivity C-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses 2011; 27:461-468.
12. MacLeod I, Rowley C, Essex M. Molecular basis for the immunostimulatory activity of abacavir via TLR-8. 19th Conference on Retroviruses and Opportunistic Infections. 5-8 March 2012, Seattle, WA, USA. Abstract 816.
13. Padilla S, Masia M, Garcia N, Jarrin I, Tormo C, Gutierrez F. Early changes in inflammatory and pro-Thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. BMC Infect Dis 2011; 11:40.
14. Palella FJ, Jr., Gange SJ, Benning L, et al. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS 2010; 24:1657-1665.
15. Martin A, Amin J, Cooper DA, et al. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS 2010; 24:2657-2663.
16. Martínez E, Larrousse M, Podzamczer D, et al. Abacavirbased therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS 2010; 24:F1-F9.
17. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39:257-265.
18. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995; 91:1314-1319.
19. Takase B, Uehata A, Akima T, et al. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol 1998; 82:1535-1539.
20. Pyke KE, Tschakovsky ME. The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function. J Physiol 2005; 568:357-369.
21. Uehata A, Lieberman EH, Gerhard MD, et al. Noninvasive assessment of endothelium-dependent flow-mediated dilation of the brachial artery. Vasc Med 1997; 2:87-92.
22. Gottdiener JS, Bednarz J, Devereux RM, et al. American Society of Echocardiography recommendations for use of echocardiography in clinical trials: a report from the American Society of Echocardiography's Guidelines and Standards Committee and The Task Force on Echocardiography in Clinical Trials Writing Committee. J Am Soc Echocardiogr 2004; 17:1086-1119.
23. McComsey G, Smith K, Patel P, et al. Similar reductions in markers of inflammation and endothelial activation after initiation of abacavir/lamivudine or tenofovir/emtricitabine: the HEAT Study. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 732.
24. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20:2043-2050.
25. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with oncedaily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010; 55:49-57.
26. Murphy RL, Berzins B, Zala C, et al. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. AIDS 2010; 24:885-890.
27. Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008; 52:569-576.
28. Yeboah J, Crouse JR, Hsu FC, et al. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 2007; 115:2390-2397.
29. Yeboah J, Folsom AR, Burke GL, et al. Events in a population-based study: the multi-ethnic study of atherosclerosis predictive value of brachial flow-mediated dilation for incident cardiovascular. Circulation 2009; 120:502-509.